{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_24", "document_index": 84, "latency_s": 1.3235749000014039, "prompt_toks": 6478, "completion_toks": 106, "relevance_score": 1.1365637e-06}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    \"Cannabis study reveals how CBD offsets the psychiatric side-effects of THC\". ScienceDaily (Press release). September 30, 2019.\n\n↑ https://www.scielo.br/j/bjmbr/a/5sGSHxqFkYHxCYhRZh6fWKH/?format=pdf&lang=en. Missing or empty |title= (help)\n\n↑ Czégény, Z; Nagy, G; Babinszki, B; Bajtel, Á; Sebestyén, Z; Kiss, T; Csupor-Löffler, B; Tóth, B; Csupor, D (26 April 2021). \"CBD, a precursor of THC in e-cigarettes\". Scientific reports. 11 (1): 8951. doi:10.1038/s41598-021-88389-z. PMC 8076212 Check |pmc= value (help). PMID 33903673.\n\n↑ Englund, A., Oliver, D., Chesney, E., Chester, L., Wilson, J., Sovi, S., De Micheli, A., Hodsoll, J., Fusar-Poli, P., Strang, J., Murray, R. M., Freeman, T. P., McGuire, P. (16 November 2022). \"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios\". Neuropsychopharmacology: 1–8. doi:10.1038/s41386-022-01478-z. ISSN 1740-634X. Retrieved 25 November 2022.\n\n\n                    Context: \n                    This excerpt highlights recent research on how cannabidiol (CBD) can counteract the psychiatric side effects of THC, including findings from a 2019 ScienceDaily article and a 2022 neuropsychopharmacology study examining different CBD:THC ratios to improve cannabis safety. It provides scientific evidence supporting CBD's role in modulating THC's adverse effects, relevant to the document's overview of CBD's pharmacology, effects, and harm reduction potential. The references emphasize CBD’s potential to influence cannabis-related mental health outcomes.\n                "}
{"metadata": {"source": "psychonaut_CSV", "row": 37, "doc_id": "doc_266", "num_chunks": 34, "chunk_id": "266::chunk_20", "document_index": 266, "latency_s": 0.7019222999952035, "prompt_toks": 4948, "completion_toks": 70, "relevance_score": 8.186364e-07}, "content": "Drug: Unknown | cid: N/A\nSource: psychonaut_CSV | Source description: ?\n\n                    Text: \n                    History and culture: \nLiterature: \nVisual effects: - The visual effects of MDA have an occurrence rating that is more selective and less consistent than any of the traditional psychedelics . The effects can never be guaranteed to manifest themselves, but are the most likely to occur with chemically pure, high dose MDA experiences, towards the end of the experience and particularly if the user has been smoking cannabis . They are also more likely to occur if the user has prior experience with psychedelics , but also remain entirely possible for those who have never tried them as well.\n\n\n                    Context: \n                    This section discusses the visual effects of MDA, highlighting their unpredictable and variable nature compared to traditional psychedelics. It explains that visual phenomena are more likely with pure, high-dose MDA, especially towards the end of the experience, and are influenced by factors such as cannabis use and prior psychedelic experience, making them less consistent and less guaranteed.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Psilocybin & Psilocin Vault : Legal Status", "description": "Information on the legal status of Psilocybin & Psilocin.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/psilocybin/psilocybin_law.shtml", "drug": "Psilocybin", "cid": 10624, "substance": "psilocybin", "category": "CHEMICALS", "erowid_column": "Law", "char_count": 7199, "word_count": 1021, "doc_id": "doc_219", "num_chunks": 9, "chunk_id": "219::chunk_6", "document_index": 219, "latency_s": 1.2673293999978341, "prompt_toks": 2082, "completion_toks": 83, "relevance_score": 6.0362476e-07}, "content": "Drug: Psilocybin | cid: 10624\nSource: erowid | Source description: Information on the legal status of Psilocybin & Psilocin.\nErowid name: psilocybin\nCategory: CHEMICALS\nField: Law\n\n                    Text: \n                    Department personnel, shall use any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the use and possession of Entheogenic Plants by adults; [... and ...] RESOLVED That the Mayor and City Council hereby declare that it shall be the policy of the City of Oakland that the investigation and arrest of adult persons for planting, cultivating, purchasing, transporting, distributing, engaging in practices with, and/or possessing Entheogenic Plants or plant compounds on the Federal Schedule 1 list shall be amongst the lowest law enforcement priority for the City of Oakland; [...]\" (last updated June 4 2019)\n\n\n                    Context: \n                    This excerpt details Oakland's local policy prioritizing decriminalization and low enforcement regarding entheogenic plants, including psilocybin mushrooms, within the broader context of the webpage's focus on drug legality and law reform at state and international levels. It highlights Oakland's specific resolution on deprioritizing investigations and arrests related to Schedule 1 entheogenic plants, emphasizing its significance in current legal and activism discussions.\n                "}
